You just read:

Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies

News provided by

Xencor, Inc.

Sep 12, 2016, 08:00 ET